The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer

BACKGROUND: Endometrial cancer (EC) is the most common gynecological malignancy in developed countries. Efficacy of the bromodomain 4 (BRD4) inhibitor JQ1 has been reported for the treatment of various human cancers, but its potential impact on EC remains unclear. We therefore aimed to elucidate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Yingxin, Bai, Gaigai, Zhao, Jing, Wei, Xuan, Li, Rui, Li, Jie, Hu, Shunxue, Peng, Lu, Liu, Peishu, Mao, Hongluan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331486/
https://www.ncbi.nlm.nih.gov/pubmed/35902869
http://dx.doi.org/10.1186/s12967-022-03545-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331486/
https://www.ncbi.nlm.nih.gov/pubmed/35902869
http://dx.doi.org/10.1186/s12967-022-03545-x

Ejemplares similares